Global Stocks Mixed as Oil Falls Ahead of US Earnings 
Trump Calls for Zelenskyy Replacement Amid Russian Diesel Deal 
South Korea Blocks 27 Crypto Exchange Websites in Regulatory Crackdown 
Asian Stocks Plunge as AI Chip Selloff Hits South Korea and Japan 
Russia Approves Sberbank for Crypto Exchange Services 
Airbus Tests Valkyrie Combat Drone in Europe for Eurofighter Integration 
Bumble Shares Surge 50% on $1 Billion Buyout Talks 
US Dollar Near 18-Month High Ahead of Inflation Data 
S&P 500 Rally Masks Losses for Over 40% of Stocks in 2026 
Moonshot AI Executives Seek Settlement Ahead of Hong Kong IPO 
Trump Secures Russian Diesel Deal as US Fuel Prices Surge 
IMF Maintains 2027 Global Growth Forecast at 3.4% Amid Rising Risks 
Samsung, SK Hynix Shares Plunge as China Chip Competition Grows 
Elon Musk Donates $366 Million to 2026 US Midterms 
Fed's Hammack Urges Faster Rate Hikes to Fight Inflation 
Most Americans Oppose Election Betting on Prediction Markets, Poll Finds 
Ethereum Foundation-Linked Wallets Move $11.13M in ETH to Kraken 
Add as a preferred source on Google
Namyang Dairy Product recently lost two of its leaders - chairman Hong Won Sik and CEO Lee Kwang Bum this week. The two decided to leave over the controversies created by the company’s claim about the effectiveness of its Bulgaris yogurt in fighting COVID-19 symptoms.
The controversy that led to Namyang’s heads exit
Chairman Hong Won Sik stepped down on Tuesday, May 4, and he announced his departure through a press conference. CEO Lee Kwang Bum also left his job on Monday, and their exit came two days after Namyang Dairy’s offices were raided by the authorities as it investigates the COVID-19 false claims.
The two resigned three weeks after the company held a symposium and announced that its Bulgaris yogurt effectively lowers the chance of contracting COVID-19 by at least 77%. However, the South Korean Ministry of Food and Drug Safety called out Namyang for such doubtful claims and immediately launched an investigation.
The public reportedly flocked to grocery stores to buy Namyang’s Bulgaris yogurts, and the company experienced a surge in its shares. This is another reason why a probe has been launched.
New scandal besetting the dairy company
Now, while the yogurt controversy is not yet over, The Korea Times reported that Namyang is facing a new issue. This time it has something to do with a patent infringement violation.
The outlet reported that Namyang’s Inner Care yogurt drink comes with a supplement pill. This is placed in the cap so it can easily be taken when drinking the yogurt. However, the company’s rival, Korea Yakult, that sells MPRO3, which is a probiotics beverage, claimed that the yogurt and pill combination was imitated by Namyang from them.
MPRO3 also comes with a supplement, and Yakult Korea is claiming that they are the originator of this product that was first launched in 2019. On the other hand, Namyang’s Inner Care was only released in February.
With the identical special features between Inner Care and MPRO3, Natural Way, which has the patent rights over Yakult Korea’s design of placing the pill inside the bottle caps, filed a patent lawsuit against Namyang. It was revealed that the filing was done last month.
